ARTICLE | Clinical News
Amarillo misses Phase III Sjogren's end point
January 5, 2001 8:00 AM UTC
AMAR said that its second U.S. Phase III trial of oral interferon alpha did not meet its primary end point of increasing Stimulated whole saliva (SWS) and reducing subjective measures of dry mouth. Ho...